Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Tongjitang Buys TCM Company with Respiratory Drug

publication date: Mar 21, 2008

Tongjitang Chinese Medicines Company will pay 25.5 million RMB ($3.5 million) to buy Qinghai Pulante Pharmaceutical Co. Ltd. Tongjitang will make unspecified additional payments over the next three years, based upon the sales of Pulante’s products. The business plan for Pulante is based on Tibetan-sourced recipes for TCM. Its lead product is Chongcao Qingfei Capsules, an OTC medication indicated for respiratory diseases, including Chronic Obstructive Pulmonary Disease, which afflicts smokers. More details...

Stock Symbol: (NYSE: TCM)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital